SAREPTA THERAPEUTICS, INC. Long-Term Debt, Maturity, after Year Five
SAREPTA THERAPEUTICS, INC. (SRPT) had Long-Term Debt, Maturity, after Year Five of $631.43 million as of 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive · last filed 2025-11-06
- 2025-09-30: Long-Term Debt, Maturity, after Year Five $631.43M.
- 2022-12-31: Long-Term Debt, Maturity, after Year Five $0.00.
- 2021-12-31: Long-Term Debt, Maturity, after Year Five $0.00.
- 2018-12-31: Long-Term Debt, Maturity, after Year Five $570.00M.
| Period end | Long-Term Debt, Maturity, after Year Five |
|---|---|
| 2025-09-30 | $631.43M 10-Q · filed 2025-11-06 |
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 |
| 2021-12-31 | $0.00 10-K · filed 2022-03-01 |
| 2018-12-31 | $570.00M 10-K · filed 2019-02-28 |
| 2017-12-31 | $570.00M 10-K · filed 2018-03-01 |
| 2016-12-31 | $880.00K 10-K · filed 2017-02-28 |
| 2015-12-31 | $1.05M 10-K · filed 2016-02-25 |
| 2014-12-31 | $1.22M 10-K · filed 2015-02-26 |
| 2013-12-31 | $1.15M 10-K · filed 2014-03-03 |
| 2012-12-31 | $1.27M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |